State Street SPDR S&P Biotech ETF (XBI) is a healthcare and biotech ETF. As of October 28, 2026, ETF Copilot scores XBI 4.9 out of 10 — highest on Growth (9.8), lowest on Quality (0.3). Its ten largest holdings are 18% of the fund.
What stands out in XBI's data
U.S. biotech industry stocks, tracked through a core index.
Its profitability lags behind most peers — the sector's high research costs eat into margins.
EBITDA margin of 12.7% trails most peers, versus a category median of 21.9%. Analysts project 44% earnings growth ahead, above the 19% peer norm.
A focused sector bet on biotech, built for portfolios that want direct exposure to drug development.
Why did XBI move this week? It rose 3.1% in the week to October 28, 2026 — Oruka Therapeutics and Twist Bioscience drove it
XBI rose 3.1% in the week to October 28, 2026. The holdings that moved it most were Oruka Therapeutics (+20.1%), Twist Bioscience (+16.3%) and Grail (+19.1%); Moderna (−12.9%) pushed the other way.
How is XBI rated? ETF Copilot scores State Street SPDR S&P Biotech ETF (XBI) 4.9 out of 10
As of October 28, 2026, ETF Copilot scores State Street SPDR S&P Biotech ETF (XBI) 4.9 out of 10 overall.
ETF Copilot scores (0–10 scale, higher is better):
- Overall: 4.9 / 10
- Growth: 9.8 / 10
- Risk: 1.2 / 10
- Quality: 0.3 / 10
- Return: 5.6 / 10
What's inside XBI?
What's inside XBI: Size (Large 16%, Mid 46%, Small 38%); Geography (International 5%, US 95%).
What are XBI's top holdings? The ten largest are 18% of the fund
Moderna, Natera, Biogen, Halozyme Therapeutics, United Therapeutics, Twist Bioscience, Abbvie, Amgen, Exelixis and Gilead Sciences are XBI's largest holdings, in that order.
Less concentrated than 96% of Health & Biotech ETFs.
Half of XBI's weight sits in its 34 largest positions, and once those weights are taken into account it behaves like 90 equally weighted holdings.
What is XBI's expense ratio? 0.35% a year
As of October 28, 2026, XBI charges 0.35% a year, yields 0.35% and holds $10.3B in assets across 163 positions.
| Measure | XBI |
|---|---|
| Expense ratio | 0.35% |
| Dividend yield | 0.35% |
| Assets under management | $10.3B |
| Holdings | 163 |
Expense ratio, dividend yield and assets under management are reported by the fund and refreshed daily. Every other figure on this page is computed by ETF Copilot.
Cite this
ETF Copilot, “State Street SPDR S&P Biotech ETF (XBI) scores and holdings analysis”, as of October 28, 2026.
https://etf-copilot.com/etf/xbi
ETF Copilot Pro unlocks XBI's price and what each holding weighs.
Try Pro free →